Artificial Intelligence
Microbot Medical Enhances Scientific Advisory Board with World Renowned Interventional Radiologists
HINGHAM, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) continues to enhance its thought leadership capabilities with the addition of several new Scientific Advisory Board (SAB) members: Stephen B. Solomon, MD, a board-certified radiologist with clinical expertise in Interventional Radiology with a focus in Tumor Ablation; Ajay K. Wakhloo, MD PhD FAHA, an internationally recognized expert in acute stroke therapy and the isolation of intracranial aneurysms and arteriovenous malformations; Gal Yaniv, MD, PhD, an endovascular neurosurgeon and leading authority on Artificial Intelligence; Dmitry J. Rabkin, MD, PhD, FSIR, a vascular and Interventional Radiology Specialist; and Ziv Neeman, MD, a vascular and interventional radiology clinician and researcher with a wide array of expertise, particularly in the field of navigation systems for minimally invasive image-guided interventional procedures.
“As we continue to develop and perfect our novel technologies, it remains critical that we also attract extraordinary capabilities throughout the organization – management, Board of Directors and Scientific Advisory Board – to leverage their combined expertise to achieve Microbot Medical’s objectives,” commented Harel Gadot, CEO, President and Chairman. “We are expecting a higher level of activity in the next year, including significant clinical and regulatory milestones, so our ability to attract leading talent and capitalize on their successes should enable us to maintain a competitive advantage and be at the forefront of developing innovative technologies to address the healthcare industry’s unmet medical needs.”
- Stephen B. Solomon, MD is Chief of the Interventional Radiology Service at Memorial Sloan Kettering, where he also holds the Enid A. Haupt Chair in Clinical Investigation. He is Director of Memorial Sloan Kettering’s Center for Image-Guided Interventions and leads a research lab that works to improve image-guided cancer interventions. He treats kidney cancer, liver cancer, lung cancer and bone cancer, has an interest in treating tumors with thermal ablation and performs hepatic artery embolization. Dr. Solomon was named a Castle Connolly: New York Magazine Top Doctor from 2012-2013 and 2015-2020. He received his undergraduate degree from Harvard, medical degree from Yale School of Medicine, and completed residencies at Yale-New Haven Hospital and The John Hopkins Hospital.
- Gal Yaniv, MD, PhD is a founder and the Chief Medical Officer at Aidoc, contributing his expertise and knowledge to help in the continuing development of advanced, healthcare grade AI. He is currently the Director, Endovascular Neurosurgery unit at Sheba – Tel HaShomer hospital. A double graduate (M.D, PhD, cum laude on both) of the Technion – Israel Institute of Technology, Dr. Yaniv completed his radiology residency at Sheba, Tel HaShomer hospital as well as diagnostic neuroradiology fellowship at Yale School of Medicine and endovascular neurosurgery fellowship at Mount Sinai Hospital. He has published numerous scientific publications focusing on basic science, radiology and public health, including a recent publication at the New England Journal of Medicine, and has presented in various scientific conferences worldwide. As a “Talpiot” alumni, he participates in the “Talpiot Medical Leadership Program” at Tel HaShomer Hospital.
- Dmitry J. Rabkin, MD, PhD, FSIR is a Vascular and Interventional Radiology Specialist, who is currently the Assistant Professor of Radiology at the Harvard Medical School and Assistant Chief of the Division of Interventional Radiology at the Brigham and Women’s Hospital. Previously, he was a Clinical Director and Chief of the Division of Interventional Radiology at the Beth Israel Deaconess Medical Center, HMS, where he completed his residency in Diagnostic Radiology and a fellowship in Vascular and Interventional Radiology. He graduated from the First Moscow Medical School. Based on his achievements and contributions to the specialty, Dr. Rabkin has been elected to Fellowship of the Society of Interventional Radiology. Dr. Rabkin has been recognized as a Castle Connolly Top Doctor and Boston Magazine Top Doctor since 2016 for his professional qualifications, reputation and clinical skills in the field of Interventional Radiology.
- Ajay K. Wakhloo, MD, PhD, FAHA is certified by the American Board of Radiology in Neuroradiology and Diagnostic Radiology, and he currently serves as Chief of Neurointerventional Radiology and Professor at TUFTS University School of Medicine. Prior to Tufts, he was a tenured Professor of Radiology, Neurology and Neurosurgery and the Director, Division NeuroImaging and Intervention (NII) in the Department of Radiology, University of Massachusetts Medical School. Earlier in his career, Dr. Wakhloo was a tenured Professor of Radiology, Neurological Surgery and Biomedical Engineering in the Department of Radiology at the University of Miami, Miller School of Medicine. He received both his medical degree and Ph.D. from the University of Mainz, Germany and completed his Internship and Residency in Internal Medicine at the University of Mainz. His training was continued at the University of Freiburg, Germany in diagnostic and interventional Neuroradiology. He also completed fellowships in Neurosurgery at the University of Freiburg and Endovascular Neurosurgery at SUNY Buffalo, as well as Research Fellowships in Neurological Surgery at Barrow Neurological Institute and in Neurosurgery at SUNY Buffalo.
- Ziv Neeman, MD is the Director of the Diagnostic Imaging Institute and Nuclear Medicine at the Haemek Medical Center (Afula, Israel). He is affiliated with the Ruth & Bruce Rapport Faculty of Medicine (Technion, Israel) as Clinical Assistant Professor in the Diagnostic Radiology Department, where he trains medical students in the field of Diagnostic Imaging. He also serves as a guideline task force member for the European Society of Gastrointestinal Endoscopy. Dr. Neeman completed fellowships at Beth Israel Deaconess (Abdominal Imaging) and Georgetown University medical center (Interventional radiology). Prior clinical roles include Section Chief of Interventional Oncology in the Diagnostic Radiology Department at the National Institutes of Health (NIH) Clinical Center (Bethesda, MD), and Chairman of the Diagnostic Imaging Institute at the Haemek Medical Center. He was a partner at Diagnostic Imaging Inc. (Philadelphia, PA), where he practiced vascular and interventional radiology, interventional oncology and diagnostic radiology. He has held academic appointments in the Diagnostic Radiology Departments at both the NIH, and the University of Maryland Medical Center (Baltimore, MD). Over the span of his career, Dr. Neeman has published dozens of academic and clinical research articles in peer reviewed journals and serves as an ad hoc reviewer. He is a graduate of Ben Gurion University of the Negev Faculty of Health Sciences medical school, and completed an Abdominal Imaging fellowship at the Beth Israel Deaconess Medical Center (affiliated to the Harvard Medical School), Boston, MA and an Interventional and Vascular Radiology fellowship at the Georgetown University Medical Center, Washington, D.C, and is currently a member of the Israel Medical Association, the Israel Radiology Association and the Radiological Society of North America (RSNA).
The new SAB members join a renowned panel of neurosurgeons and thought leaders in robotic medical technologies, including Prof. Moshe Shoham. Prof. Shoham is the co-founder of Microbot Medical and founder of Mazor Robotics. The Company believes that the combined contributions from their diverse sets of expertise will help drive development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot’s current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).
Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available at http://www.microbotmedical.com.
Safe Harbor
Statements pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary closing conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY™ and SCS, the outcome of its studies to evaluate LIBERTY, SCS and other existing and future technologies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Investor Contact:
Michael Polyviou
EVC Group
[email protected]
732-933-2754
Artificial Intelligence
Reliance Cyber and Google Cloud Security unite to transform cybersecurity for UK businesses
LONDON, May 28, 2024 /PRNewswire/ — Leading Managed Security Service Provider (MSSP), Reliance Cyber has been selected as one of only four MSSPs to partner with Google Cloud Security (GCS). This collaboration is set to make cybersecurity more effective and less complicated for businesses throughout the UK and Ireland.
Why this matters:In today’s complex security environment, businesses face a multitude of challenges, including escalating cyberattacks, an overwhelming number of security alerts, rising cybersecurity costs, and a critical shortage of skilled professionals. The partnership between Reliance Cyber and Google Cloud Security provides organisations with improved security postures through insightful, data-driven analytics, which underpin Reliance Cyber’s XDR service. For businesses facing diverse economic, social, and technological changes—such as the ongoing impacts of COVID-19, the transition to hybrid and remote work, rapid technological advancements like AI, and budget pressures from the cost of living crisis—this partnership represents a significant step forward. It enhances cybersecurity without the usual challenges of high costs, complexity, or the need for specialised staff. It’s about making world-class security simple and available to a wider audience.
What’s changing:
Support for growth: The partnership will expand the reach of state-of-the-art security services to more businesses, helping to protect organisations without the stress of financial and operational barriersEnhanced visibility, lower costs: Leveraging Google’s SOAR capabilities and Chronicle’s powerful telemetry, Reliance Cyber’s tailored ingestion approach means organisations can achieve enhanced visibility across their digital environments at a reduced cost. This approach enables proactive prevention and detection of threats, ensuring better security with less expenditure.Key benefits of the strategic partnership include:
AI and automation: Automation is at the core of Reliance Cyber’s offering. Every alert is enriched with threat intel from leading vendors, automatically correlated, and grouped into cases, reducing mean time to detect (MTTD) and mean time to respond (MTTR). Google’s additions enhance this with lower data ingestion costs, superior threat intelligence, curated detections, and advanced anomaly detection using machine learningSimplified security operations to support staff: Integration of Google Cloud’s SOAR capabilities simplifies the security management landscape, allowing CISOs to focus on strategic planning rather than daily operational hurdlesScalable security for business growth: The partnership supports business expansion strategies by providing scalable security solutions that grow with the company, crucial for organisations driving technological advancementData-driven insights for better decision-making: Boards will gain unparalleled visibility into their digital environments, fostering smarter, faster decision-making to preemptively address potential security threats.Rob Walton, Chief Revenue Officer at Reliance Cyber, on the transformative impact: “We’re thrilled to partner with Google Cloud Security. This partnership aligns perfectly with our mission to deliver comprehensive, advanced security services to the market, making top-level security accessible and manageable for businesses of all sizes. Ultimately, it’s about creating predictability and peace of mind in an area that can often cause businesses and their boards sleepless nights, particularly due to concerns about attacks and the financial constraints that dictate risk appetites.”
Do you want more coverage, at less cost, with zero compromises?
Enquire about a proof of concept. Visit: https://eu1.hubs.ly/H09bKtG0.
About Reliance Cyber
Since our founding in 2003, Reliance Cyber has established itself as a leading Managed Security Service Provider (MSSP). By combining deep cybersecurity expertise with a true partnership ethos, we enable organisations to concentrate on their core business.
Logo – https://mma.prnewswire.com/media/2418301/Reliance_Cyber.jpgLogo – https://mma.prnewswire.com/media/2418300/Google_Cloud.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/reliance-cyber-and-google-cloud-security-unite-to-transform-cybersecurity-for-uk-businesses-302156568.html
Artificial Intelligence
Eficode acquires Jodocus and reinforces Atlassian Cloud skills and Atlassian partnership in Germany
HELSINKI, May 28, 2024 /PRNewswire/ — Eficode has acquired Jodocus, the first cloud-native Atlassian Platinum partner in Germany. This acquisition further reinforces Eficode’s role as an Atlassian partner in Germany and expands its skills and services in Atlassian Cloud.
“Atlassian is moving to the Cloud, and the related know-how is essential to speed up this transition. Jodocus was originally the first Atlassian partner in Germany to focus fully on the Cloud. Their broad expertise in Atlassian tools and cloud migrations helps our customers in their journey to the cloud and complements our mission to build the future of software development,” says Ilari Nurmi, CEO of Eficode. “We welcome Jodocus’ employees and customers to Eficode.”
Founded in 2019, Jodocus is an Atlassian Platinum Solution Partner with extensive expertise in Atlassian Cloud. In addition to focusing on the Cloud, the Jodocus team offers support on business processes, Application Lifecycle Management, and DevOps. Their customer base is in Germany, with well-known names such as Otto Group and Fricke. Jodocus has 45 employees, and its revenue in 2023 was 11,5 million euros. “Together, Eficode and Jodocus will form a more significant entity and have even more international customers, which opens possibilities for deepening and broadening our relationship with our customers,” says Werner Krandick, CEO of Jodocus.
Eficode has enabled countless businesses with DevOps and digital transformation to adopt new technologies and practices to create software better. Its full spectrum of digital services can now be extended also to Jodocus’ customers. Eficode ROOT provides software development tools as a managed service in a Software-as-a-Service manner. In turn, with Total Support, we manage the tools and offer support, coaching, and mentoring for Atlassian solutions as a subscription.
In recent years, Eficode has grown strongly both organically and through acquisitions. Eficode’s compound annual growth (CAGR) during the previous four fiscal years has been 70%.
Media contactsIlari Nurmi, Chief Executive Officer, Eficode. [email protected], +358 40 577 5084 Lauri Palokangas, Chief Marketing Officer, Eficode. [email protected], +358 50 486 4918
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eficode-oy/r/eficode-acquires-jodocus-and-reinforces-atlassian-cloud-skills-and-atlassian-partnership-in-germany,c3988509
The following files are available for download:
https://news.cision.com/eficode-oy/i/eficode-acquires-jodocus,c3304183
eficode acquires jodocus
View original content:https://www.prnewswire.co.uk/news-releases/eficode-acquires-jodocus-and-reinforces-atlassian-cloud-skills-and-atlassian-partnership-in-germany-302156539.html
Artificial Intelligence
New first of its kind UK legal-tech recruitment platform aims to put an end to overseas worker scams
Unique UK-based legal technology platform, Immpact, helps unite the global talent market to fulfil UK skills shortages across healthcare, construction, engineering, life sciences and hospitality Immpact directly connects employers, recruiters and regulated legal experts with pre-qualified global talent – and aims to help eradicate profiteering job scammersREADING, England, May 28, 2024 /PRNewswire/ — A unique new legal-tech recruitment platform has launched in the UK to help put an end to overseas worker scams and directly connect UK employers and recruiters with pre-qualified overseas global talent. Immpact will help fulfil acute skills shortages across sectors including healthcare, construction, engineering, life sciences and hospitality, while ensuring full legal Home Office compliance.
The launch of Immpact follows over two years of advanced legal-tech development. Using the immigration law expertise of Founder and Managing Director, Jonathan Beech, and his team of specialists, the platform will help unite a previously disconnected global talent market with under-resourced UK employers and transform global workplace migration. Immpact has also been developed through discussions with hundreds of employers, industry bodies and overseas talent.
With job scams – from fake jobs to illegal fees for sponsor licences – ongoing, particularly in the social and healthcare sector, Immpact will ensure only pre-qualified talent, employers and recruitment firms are placed on its platform following stringent multi-layer checks. This will ensure that all jobs and talent are qualified and genuine along with thoroughly regulated employers and recruiters, to provide a global marketplace for talent.
Jonathan Beech, Founder and Managing Director of Immpact, said: “Through my existing business running Migrate UK, I’m acutely aware of the issues that UK employers and recruiters are having in trying to fulfil talent shortages across sectors such as care, healthcare and life sciences. I also regularly hear terrible stories of genuine overseas job hunters being ripped off in their home countries or the UK by job scammers, often running to thousands of pounds.
“I knew there had to be a better way to match pre-qualified overseas talent with genuine work opportunities and responsible UK employers – effectively a ‘talent’ match-making site which is designed to eradicate scammers to provide a global, trusted marketplace for talent.”
Following the latest government immigration rule changes, overseas recruitment costs are continuing to rise for businesses struggling with talent shortages. From 4 April 2024, the minimum salary for entering the new skilled visa worker route for the first time increased by 48%, from £26,200 to £38,700 a year. There are different rates for those already holding a skilled worker certificate of sponsorship prior to this date and discounts are available for key shortage roles on the Immigration Salary List (ISL).
Immpact will benefit employers and recruiters by saving them time and money. Working with recruitment experts to analyse existing overseas recruitment workflows, Immpact has calculated that it will save 50% of the time involved in managing overseas recruitment, helping to cut down the time-consuming filtering of applications traditionally needed.
For employers traditionally looking to recruit overseas applicants, previous data from industry recruitment software specialists show that 30% of overseas applications are rejected as they do not have the right to work, while 64% are rejected due to CVs being unclear or requirements not being met. This leaves just 6% of applications remaining, which results in about 2% then being interviewed. Immpact will automatically present only suitable pre-qualified applications to employers or recruiters, eradicating wasted time on unsuitable or unqualified applicants.
Beech continues: “Following thousands of hours of development and utilising the latest advanced technology which can adapt to evolving Home Office requirements and procedures, we’re proud to launch Immpact. Our unique new platform takes care of the entire process – from pre-qualifying processes, searching and shortlisting, down to arranging interviews, successful appointments, onboarding, the provision of regular content and guidance, and access to regulated immigration legal professionals.
“Our new technology will transform global migration for both UK organisations and businesses struggling to recruit and global talent looking to work in the UK. Immpact has been thoroughly tested at every stage and is both user-friendly and, crucially, compliant, so qualified overseas applicants and UK employers and recruiters can be confident that only genuine UK jobs and overseas applicants match and proceed. Quite simply, we want Immpact to simplify the whole migration process by putting the right talent in the right place at the right time, and for UK employers to fulfil critical talent shortages which will help them not only survive, but thrive.”
The platform has a free trial or low-cost subscriber options for search-matching and more for employers and recruiters. For talent, the platform has zero costs for creating a profile, using the pre-qualifying tools or searching for opportunities. For further information visit www.immpact.ai.
Photo – https://mma.prnewswire.com/media/2421643/Founder_and_Managing_Director_Immpact.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/new-first-of-its-kind-uk-legal-tech-recruitment-platform-aims-to-put-an-end-to-overseas-worker-scams-302155226.html
-
Artificial Intelligence4 days ago
Titans of Tech: GP Bullhound releases its annual report on the European tech ecosystem
-
Uncategorized4 days ago
GienTech Hosted the “2024 GienTech Digital Transformation Conference” to Promote Overseas Collaborative Ecosystem Development
-
Uncategorized4 days ago
Hyreo ushers in a New Dawn for Recruitment Technology with Hyreo Labs
-
Artificial Intelligence4 days ago
Bybit Web3 Announces Upcoming IDO for Aperture Finance, Simplifying Web3 Finance
-
Artificial Intelligence6 days ago
HONOR Unveils Four-Layer AI Architecture and Forges Ahead with Google Cloud for More AI Experiences at VivaTech 2024
-
Artificial Intelligence4 days ago
Overseas Expansion Strategy of K-OTT Introduced in France, KOCCA holds the ‘2024 Korea-France Content Forum’
-
Artificial Intelligence4 days ago
Northern Data Group’s Peak Mining, announces purchase of a second 300MW data center location in Corpus Christi, Texas
-
Artificial Intelligence4 days ago
IoT Node and Gateway Market worth $604.7 billion by 2029 – Exclusive Report by MarketsandMarkets™